new glp 1 agonist novo nordisk Nordisk's weight-loss pill wins FDA approval Diabetes Treatments | Novo Nordisk

Tirzepatide for managing overweight and obesity

With an interdisciplinary focus, practitioners utilize ophthalmic imaging, neuroimaging, laboratory evaluation, electrophysiology, pathologic evaluation, and genetic testing to evaluate patients

Arakawa M, Ebato C, Mita T, Hirose T, Kawamori R, Fujitani Y, et al

There are three meta-analyses that examined whether GLP-1RA use was associated with increased risk for PDAC compared to the control arms (a combination of placebo and other diabetes medications)

In general, DPP-4 inhibitors are effective at promoting moderate lowering of A1C and are associated with few adverse events